New product [Regulatives / Guidelines]

posted by Ohlbe – France, 2020-03-11 17:54 (361 d 22:55 ago) – Posting: # 21257
Views: 3,246

Dear SKM,

» Both the APIs are registered and marketed as separate formulation. We are mixing these two at same ratio into one formulation without adding any new excipients. I don't know why will it be considered as a new product. Can you guide me please?

Well, you are giving all the arguments yourself: up to now the two active substances are only marketed as separate formulations. You will be mixing them into one new formulation, which has never been tested or marketed before. Sorry, but I can't explain more.

Regards
Ohlbe

Complete thread:

Activity
 Admin contact
21,371 posts in 4,463 threads, 1,495 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Monday 16:49 CET (Europe/Vienna)

When puzzled, it never hurts to read the primary documents 
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5